Directing novel ChoKα1 inhibitors using MamC-mediated biomimetic magnetic nanoparticles: a way to improve specificity and efficiency
Bioorganic Chemistry · 2024-10 · 151 · 107693
DOI: 10.1016/j.bioorg.2024.107693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024-10. Verfasst von Alberto Sola-Leyva und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada, Granada 18071, Spain; Instituto de Investigación Bios…. Hauptthemen laut MEDLINE: Choline Kinase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Junta de Andalucía, Junta de Andalucia, Ministerio de Economía y Competitividad.
Abstract (Originalsprache)
Targeting phospholipid biosynthesis, specifically phosphatidylcholine (PC), which is enhanced in tumor cells, has been proven a suitable antitumor strategy. In fact, the overexpression of the choline kinase α1 (ChoKα1) isoform has been found in malignant cells and tumors, thus becoming an excellent antitumor target. ChoKα1 inhibitors are being synthesized at the present that show a large inhibitory activity. Two of them have been chosen in this study as representatives of different structural families: a biscationic biphenyl derivative of thieno[3,2-d]pyrimidinium substituted with a cyclic amine (here referred to as Fa22) and a biscationic biphenyl thioethano derivative of 7-chloro-quinolinium substituted with a pyrrolidinic moiety (here referred to as PL48). However, the potential use of these types of compounds in systemic treatments is hampered because of their low specificity. In fact, to enter the cell and reach their target, these inhibitors use choline transporters and inhibit choline uptake, being that one of the causes of their toxicity. One way to solve this problem could be allowing their entrance into the cells by alternative ways. With this goal, MamC-mediated magnetic nanoparticles (BMNPs), already proven effective drug nanocarriers, have been used to immobilize Fa22 and PL48. The idea is to let BMNPs enter the cell (they enter the cell by endocytosis) carrying these molecules, and, therefore, offering another way in for these compounds. In the present study, we demonstrate that the coupling of Fa22 and PL48 to BMNPs allows these molecules to enter the tumoral cell without completely inhibiting choline uptake, so, therefore, the use of Fa22 and PL48 in these nanoformulations reduces the toxicity compared to that of the soluble drugs. Moreover, the nanoassemblies Fa22-BMNPs and PL48-BMNPs allow the combination of chemotherapy and local hyperthermia therapies for a enhanced cytotoxic effect on the tumoral HepG2 cell line. The consistency of the results, independently of the drug structure, may indicate that this behavior could be extended to other ChoKα1 inhibitors, opening up a possibility for their potential use in clinics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada, Granada 18071, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada 18014, Spain. Electronic address: albert…
- Department of Microbiology, Faculty of Sciences, University of Granada, Granada 18071, Spain. Electronic address: yjabalera@ugr.es.
- Department of Microbiology, Faculty of Sciences, University of Granada, Granada 18071, Spain. Electronic address: monicajc@correo.ugr.es.
- NanoMag Lab. Department of Applied Physic, Faculty of Science, University of Granada, Granada 18071, Spain.
- Department of Microbiology, Faculty of Sciences, University of Granada, Granada 18071, Spain.
- Department of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada, Granada 18071, Spain.
Förderung
- Junta de Andalucía
- Junta de Andalucia
- Ministerio de Economía y Competitividad
Zitieren
APA
Sola-Leyva, A., Jabalera, Y., Jimenez-Carretero, M., Lázaro, M., Pozo-Gualda, T., García-Vargas, P. J., Luque-Navarro, P. M., Fasiolo, A., López-Cara, L. C., Iglesias, G. R., Paz Carrasco-Jiménez, M., & Jiménez-López, C. (2024). Directing novel ChoKα1 inhibitors using MamC-mediated biomimetic magnetic nanoparticles: a way to improve specificity and efficiency. Bioorganic Chemistry, 151, 107693. https://doi.org/10.1016/j.bioorg.2024.107693
Vancouver
Sola-Leyva A, Jabalera Y, Jimenez-Carretero M, Lázaro M, Pozo-Gualda T, García-Vargas PJ, et al. Directing novel ChoKα1 inhibitors using MamC-mediated biomimetic magnetic nanoparticles: a way to improve specificity and efficiency. Bioorganic Chemistry. 2024;151:107693. doi:10.1016/j.bioorg.2024.107693
BibTeX
@article{SolaLeyva2024,
author = {Sola-Leyva, Alberto and Jabalera, Ylenia and Jimenez-Carretero, Monica and Lázaro, Marina and Pozo-Gualda, Tamara and García-Vargas, Pedro J and Luque-Navarro, Pilar M and Fasiolo, Alberto and López-Cara, Luisa C and Iglesias, Guillermo R and Paz Carrasco-Jiménez, María and Jiménez-López, Concepción},
title = {Directing novel ChoKα1 inhibitors using MamC-mediated biomimetic magnetic nanoparticles: a way to improve specificity and efficiency},
journal = {Bioorganic Chemistry},
year = {2024},
volume = {151},
pages = {107693},
doi = {10.1016/j.bioorg.2024.107693}
}
EUVIMED